A detailed history of Cutler Group LP transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Cutler Group LP holds 3,000 shares of TGTX stock, worth $87,420. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,000
Previous 2,080 44.23%
Holding current value
$87,420
Previous $35,000 54.29%
% of portfolio
0.01%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 18, 2024

SELL
$6.68 - $18.81 $18,169 - $51,163
-2,720 Reduced 56.67%
2,080 $35,000
Q3 2023

Nov 07, 2023

BUY
$8.36 - $26.5 $33,440 - $106,000
4,000 Added 500.0%
4,800 $40,000
Q2 2023

Jul 18, 2023

BUY
$15.48 - $35.0 $4,644 - $10,500
300 Added 60.0%
800 $19,000
Q2 2022

Aug 04, 2022

SELL
$3.74 - $10.66 $21,082 - $60,090
-5,637 Reduced 91.85%
500 $2,000
Q1 2022

Apr 14, 2022

BUY
$7.81 - $20.45 $36,839 - $96,462
4,717 Added 332.18%
6,137 $58,000
Q4 2021

Jan 18, 2022

SELL
$15.2 - $35.51 $42,864 - $100,138
-2,820 Reduced 66.51%
1,420 $26,000
Q3 2021

Oct 26, 2021

BUY
$21.78 - $40.45 $48,787 - $90,608
2,240 Added 112.0%
4,240 $141,000
Q2 2021

Jul 19, 2021

BUY
$32.5 - $48.96 $24,407 - $36,768
751 Added 60.13%
2,000 $77,000
Q4 2020

Jan 21, 2021

SELL
$25.27 - $54.9 $135,219 - $293,769
-5,351 Reduced 81.08%
1,249 $64,000
Q2 2020

Jul 22, 2020

BUY
$8.9 - $21.84 $58,348 - $143,183
6,556 Added 14900.0%
6,600 $128,000
Q4 2018

Feb 05, 2019

SELL
$3.44 - $5.76 $15,136 - $25,344
-4,400 Reduced 99.01%
44 $0
Q3 2018

Nov 07, 2018

BUY
$5.15 - $14.0 $22,660 - $61,600
4,400 Added 10000.0%
4,444 $24,000
Q2 2018

Aug 10, 2018

SELL
$12.5 - $15.0 $32,500 - $39,000
-2,600 Reduced 98.34%
44 $0
Q1 2018

May 11, 2018

SELL
$8.7 - $16.8 $15,503 - $29,937
-1,782 Reduced 40.26%
2,644 $37,000
Q4 2017

Jan 17, 2018

BUY
$7.35 - $12.3 $1,631 - $2,730
222 Added 5.28%
4,426 $36,000
Q3 2017

Oct 17, 2017

BUY
$10.0 - $12.7 $42,040 - $53,390
4,204
4,204 $49,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.23B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.